ST Germain D J Co. Inc. Buys 14,058 Shares of Zimmer Biomet Holdings, Inc. $ZBH

ST Germain D J Co. Inc. increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 127,931 shares of the medical equipment provider’s stock after buying an additional 14,058 shares during the period. ST Germain D J Co. Inc. owned about 0.06% of Zimmer Biomet worth $12,601,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC bought a new position in shares of Zimmer Biomet in the 4th quarter worth $204,000. Public Sector Pension Investment Board raised its holdings in Zimmer Biomet by 11.4% in the first quarter. Public Sector Pension Investment Board now owns 27,284 shares of the medical equipment provider’s stock worth $3,088,000 after purchasing an additional 2,789 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Zimmer Biomet by 13.3% during the first quarter. Russell Investments Group Ltd. now owns 82,897 shares of the medical equipment provider’s stock valued at $9,362,000 after buying an additional 9,758 shares during the last quarter. Cresset Asset Management LLC boosted its holdings in shares of Zimmer Biomet by 16.2% in the 1st quarter. Cresset Asset Management LLC now owns 43,219 shares of the medical equipment provider’s stock valued at $4,902,000 after buying an additional 6,011 shares in the last quarter. Finally, Raymond James Financial Inc. grew its position in shares of Zimmer Biomet by 195.5% in the 1st quarter. Raymond James Financial Inc. now owns 594,097 shares of the medical equipment provider’s stock worth $67,240,000 after buying an additional 393,077 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 1.7%

NYSE:ZBH opened at $90.90 on Wednesday. The company has a market capitalization of $18.01 billion, a P/E ratio of 22.50, a PEG ratio of 2.43 and a beta of 0.61. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. Zimmer Biomet Holdings, Inc. has a 12 month low of $85.33 and a 12 month high of $114.44. The firm has a fifty day simple moving average of $95.35 and a 200-day simple moving average of $96.73.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The company had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same quarter last year, the business posted $1.74 EPS. The firm’s quarterly revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ZBH shares. JPMorgan Chase & Co. restated a “neutral” rating and issued a $100.00 target price (down from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. UBS Group decreased their price objective on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating for the company in a report on Thursday, November 6th. Canaccord Genuity Group lowered their price objective on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research report on Monday, November 10th. Barclays dropped their target price on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a research note on Wednesday, November 5th. Finally, Rothschild & Co Redburn assumed coverage on Zimmer Biomet in a research note on Thursday, September 18th. They issued a “buy” rating and a $130.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $107.50.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.